Buy Aduhelm (aducanumab-avwa)
What is Aduhelm (aducanumab-avwa) for?
Aduhelm (aducanumab-avwa) is an amyloid beta-directed antibody used to treat people with mild cognitive impairment or mild dementia.[1]
It is the first novel therapy approved for Alzheimer’s disease since 2003, and the first disease-modifying therapy for Alzheimer’s, targeting the underlying cause of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.[1]
It is available in vial form for intravenous infusion, containing either 170 mg/1.7 mL (100 mg/mL) and 300 mg/3 mL (100 mg/mL) aducanumab-avwa.[1]
How does Aduhelm (aducanumab-avwa) work?
The active ingredient in Aduhelm, aducanumab-avwa, is a human-made antibody that is designed to remove toxic clumps (plaques) of the protein beta-amyloid. These plaques are thought to drive the death of nerve cells (neurons) in the brains of people with Alzheimer’s disease and cause symptoms of the disease.[2]
Aduhelm is thought to bind to and reduce the amount of plaques in the brain of people with Alzheimer’s, thereby slowing down the progression of the disease.[2]
Where has Aduhelm (aducanumab-avwa) been approved?
Aduhelm (aducanumab-avwa) was approved for the treatment of people with Alzheimer’s Disease by:
- The Food and Drug Administration (FDA), USA on June 7, 2021.[3]
Aduhelm (aducanumab-avwa) was approved under Accelerated approval, based on the reduction of amyloid beta plaque size.[3]
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Aduhelm (aducanumab-avwa) taken?
The standard dosage is:[1]
- Built up stepwise (titrated) up to 10 mg/kg body weight at the start of treatment
- Followed by a 10 mg/kg maintenance dose
Aduhelm (aducanumab-avwa) is administered through an IV line (intravenous) over approximately one hour every four weeks and at least 21 days apart.[1]
Magnetic resonance imaging (MRI) scans will be done before and during treatment to check for Amyloid Related Imaging Abnormalities (ARIA).[1]
Complete information about Aduhelm (aducanumab-avwa) dosage and administration can be found in the official prescribing information listed in our references section.[1]
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Aduhelm (aducanumab-avwa)?
Common adverse reactions
The most common side effects ( ≥10% of patients and higher incidence compared to placebo) listed in the prescribing information include:[1]
- Fluid accumulation in the brain (Amyloid Related Imaging Abnormalities (ARIA) edema)
- Headache
- ARIA-H microhemorrhage
- ARIA-H superficial siderosis
- Fall
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include:[1]
- Amyloid Related Imaging Abnormalities (ARIA)
- Hypersensitivity reactions
Use in a specific population
It is not yet known if Aduhelm (aducanumab-avwa) is fatal for a fetus, it is advised to avoid pregnancies. It is not known if Aduhelm (aducanumab-avwa) passes into your breast milk. Discuss with your treating doctor if you are pregnant or plan to become pregnant or are breastfeeding or plan to breastfeed.[1]
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.[1]
References
1. Full prescribing information [FDA]: Aduhelm (aducanumab-avwa) [PDF]
Biogen, Jun 2021
2. Aducanumab
Alzheimersnewstoday.com, cited Jun 2021
3. FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Biogen, Jun 2021
Reviews
There are no reviews yet.